jy09
Peptideexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02971722)
Timeline
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- jy09
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06257966 | Phase 3 | Jul 17, 2024 | Beijing Dongfang Biotech Co., Ltd., Peking University |
| NCT06254014 | Phase 3 | Jul 10, 2024 | Beijing Dongfang Biotech Co., Ltd., Peking University |
| NCT06247748 | Phase 1 | Oct 19, 2023 | Beijing Dongfang Biotech Co., Ltd. |
| NCT04354090 | Phase 1 | Apr 26, 2018 | Beijing Dongfang Biotech Co., Ltd., Nanjing University |
| NCT02971722 | Phase 1 | Dec 1, 2016 | Beijing Dongfang Biotech Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Dongfang Biotech Co., Ltd. | For profit | 5 | 5 | 2 | 2016 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Nanjing University | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1